Testing a new drug for low-risk MDS or CCUS with an SF3B1 mutation
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental medicine called REGN17235 to see if it is safe and tolerable for people with certain blood conditions, specifically low-risk MDS or CCUS with a specific gene change (SF3B1 mutation). It aims to help improve blood cell production and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a mutation in the SF3B1 gene, which is often linked to certain blood disorders.
- You must have either low-risk myelodysplastic syndrome (MDS) or clonal cytopenia of undetermined significance (CCUS) – both are conditions where the bone marrow doesn't make enough healthy blood cells.
- Your liver and kidneys must work well enough, and you may need red blood cell transfusions.
- You cannot have anemia caused by other things like low iron, low vitamin B12, or bleeding in the last 3 months.
- You cannot have had other cancer treatment recently, and you must not have had a bone marrow transplant in the last 100 days or have graft-versus-host disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
This Phase 2 trial studies whether a statin medicine can help people with CCUS (a bone-marrow condition with abnormal genetic mutations) or lower-risk MDS (a blood disorder) that causes persistent low blood counts. It aims to see if statins can improve blood-related outcomes while keeping you safe from side effects.
This trial tests an early treatment for people with a condition called high-risk CCUS, where low blood counts and gene changes raise the risk of developing blood cancer. The goal is to see if intervening early can prevent or delay progression to leukemia or MDS.
This trial tests a drug called pacritinib in people with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasms (MDS/MPN). The drug targets several proteins that may help control the disease, especially for those who have not responded to other treatments.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
Hear when a new Clonal Cytopenia of Undetermined Significance (CCUS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.